Fig. 3.
Fig. 3. Ultrastructural changes occurring in the fractionated cell populations recovered 2 hours after apoptotic induction. / (A) Sizeable proportions of activated T cells sedimenting in the F3 and F4 fractions of Percoll gradients after CD2 signaling display partial chromatin condensation. F2-I cells were exposed for 2 hours to anti-CD2, fractionated on density Percoll gradients, and examined by electron microscopy. Values inside the brackets are the percentages of cells displaying the same morphology as that represented in the pictures. (Bi) In the CD2 system, the presence of BOC-D.fmk (50 μmol/L) during apoptotic induction does not prevent the appearance of F5 cells with partial chromatin condensation, contrasting with the strong condensation seen in F5 cells generated in the absence of caspase inhibitor. (Bii) Cells treated with anti-CD95 in the presence of BOC-D.fmk retain a normal nuclear morphology and are still recovered in the low buoyant density fraction of Percoll gradients (at the level of F2-II).

Ultrastructural changes occurring in the fractionated cell populations recovered 2 hours after apoptotic induction.

(A) Sizeable proportions of activated T cells sedimenting in the F3 and F4 fractions of Percoll gradients after CD2 signaling display partial chromatin condensation. F2-I cells were exposed for 2 hours to anti-CD2, fractionated on density Percoll gradients, and examined by electron microscopy. Values inside the brackets are the percentages of cells displaying the same morphology as that represented in the pictures. (Bi) In the CD2 system, the presence of BOC-D.fmk (50 μmol/L) during apoptotic induction does not prevent the appearance of F5 cells with partial chromatin condensation, contrasting with the strong condensation seen in F5 cells generated in the absence of caspase inhibitor. (Bii) Cells treated with anti-CD95 in the presence of BOC-D.fmk retain a normal nuclear morphology and are still recovered in the low buoyant density fraction of Percoll gradients (at the level of F2-II).

Close Modal

or Create an Account

Close Modal
Close Modal